Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05881421




Registration number
NCT05881421
Ethics application status
Date submitted
19/05/2023
Date registered
31/05/2023
Date last updated
31/05/2023

Titles & IDs
Public title
DISRUPT PAD III Observational Study
Scientific title
Prospective Multi-Center, Post-Market, Observational Study (OS) of the Shockwave Medical, Inc. Intravascular Lithotripsy System in Peripheral Arteries
Secondary ID [1] 0 0
CP 60892 OS
Universal Trial Number (UTN)
Trial acronym
PAD III OS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Peripheral Arterial Disease 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Observational [Patient Registry]
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Procedural Success - Primary Effectiveness Endpoint
Timepoint [1] 0 0
Peri-procedural, approximately 2 hours
Secondary outcome [1] 0 0
Procedural Success - Secondary Effectiveness Endpoint
Timepoint [1] 0 0
Peri-procedural, approximately 2 hours

Eligibility
Key inclusion criteria
Subjects were required to meet ALL of the following inclusion criteria in order to be
included in this clinical study:

1. Subjects intended to be treated with Shockwave Medical Lithoplasty for de-novo or
restenotic lesions of the femoral, ilio-femoral, popliteal, and infra-popliteal
arteries.

2. Subjects presenting with claudication or CLI by Rutherford Clinical Category 2, 3, 4,
5, or 6 of the target limb.

3. Age of subject is > 18.

4. Subject of subject's legal representative have been informed of the nature of the
study, agrees to participate and has signed the approved consent form.

5. Calcification is at least moderate defined as presence of fluoroscopic evidence of
calcification: 1) on parallel sides of the vessel and 2) extending > 50% the length of
the lesion if lesion is =50mm in length; or extending for minimum of 20mm if lesion is
<50mm in length.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Subjects that met ANY of the following exclusion criteria were not included in this
clinical study:

1. Subjects with any medical condition that would make him/her an inappropriate candidate
for treatment with Shockwave Lithoplasty as per Instructions for Use (IFU) or
investigator's opinion.

2. Subject already enrolled in other investigational (interventional) studies that would
interfere with study endpoints.

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
16/11/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
10/06/2021
Sample size
Target
Accrual to date
Final
1373
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
District of Columbia
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Iowa
Country [8] 0 0
United States of America
State/province [8] 0 0
Massachusetts
Country [9] 0 0
United States of America
State/province [9] 0 0
Michigan
Country [10] 0 0
United States of America
State/province [10] 0 0
Mississippi
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
Oklahoma
Country [16] 0 0
United States of America
State/province [16] 0 0
Oregon
Country [17] 0 0
United States of America
State/province [17] 0 0
Pennsylvania
Country [18] 0 0
United States of America
State/province [18] 0 0
Rhode Island
Country [19] 0 0
United States of America
State/province [19] 0 0
Tennessee
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
West Virginia
Country [22] 0 0
Germany
State/province [22] 0 0
Mülheim
Country [23] 0 0
Germany
State/province [23] 0 0
Münster
Country [24] 0 0
Germany
State/province [24] 0 0
Rosenheim
Country [25] 0 0
New Zealand
State/province [25] 0 0
Auckland

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Shockwave Medical, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The Disrupt PAD III study was designed as a randomized controlled trial (RCT) with an
additional observational registry component. The registry, referred to as the Disrupt PAD III
Observational Study (PAD III OS), was a global, prospective, multi-center, single-arm
registry of the Shockwave Peripheral Intravascular Lithotripsy (IVL) System. The objective of
this study was to assess the real-world acute performance of IVL in the treatment of
calcified, stenotic, peripheral arteries that may not qualify for inclusion in the RCT. The
study was designed to enroll a maximum of 1500 subjects from up to 60 global sites with a
minimum of 200 subjects treated with the S4 IVL catheter, a line extension designed to treat
smaller diameter peripheral vessels, including calcified below-the-knee (BTK) lesions.

Subjects were required to have target lesions in the iliac, femoral, ilio-femoral, popliteal,
or infra-popliteal arteries with at least moderate calcification as determined by the
investigator, defined as calcification within the lesion on both sides of the vessel assessed
by angiography. Adjunctive therapies such as atherectomy, specialty balloons, and stents were
allowed. Subjects were followed through discharge.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05881421
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries